CN111886243A - 非-hla限制性t细胞受体及其用途 - Google Patents

非-hla限制性t细胞受体及其用途 Download PDF

Info

Publication number
CN111886243A
CN111886243A CN201980019097.1A CN201980019097A CN111886243A CN 111886243 A CN111886243 A CN 111886243A CN 201980019097 A CN201980019097 A CN 201980019097A CN 111886243 A CN111886243 A CN 111886243A
Authority
CN
China
Prior art keywords
cell
tcr
antigen
locus
recombinant tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980019097.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·塞德莱恩
J·A·曼西利亚-索托
J·埃康
A·多布里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN111886243A publication Critical patent/CN111886243A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980019097.1A 2018-02-11 2019-02-11 非-hla限制性t细胞受体及其用途 Pending CN111886243A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629072P 2018-02-11 2018-02-11
US62/629,072 2018-02-11
PCT/US2019/017525 WO2019157454A1 (en) 2018-02-11 2019-02-11 Non-hla restricted t cell receptors and uses thereof

Publications (1)

Publication Number Publication Date
CN111886243A true CN111886243A (zh) 2020-11-03

Family

ID=67548607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980019097.1A Pending CN111886243A (zh) 2018-02-11 2019-02-11 非-hla限制性t细胞受体及其用途

Country Status (12)

Country Link
US (3) US20200368283A1 (https=)
EP (1) EP3749687A4 (https=)
JP (3) JP2021513347A (https=)
KR (1) KR102828999B1 (https=)
CN (1) CN111886243A (https=)
AU (2) AU2019216982B2 (https=)
BR (1) BR112020016138A2 (https=)
CA (1) CA3090791A1 (https=)
IL (2) IL314563A (https=)
MX (1) MX2020008390A (https=)
SG (1) SG11202007622SA (https=)
WO (1) WO2019157454A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022179545A1 (zh) * 2021-02-25 2022-09-01 华夏英泰（北京）生物技术有限公司 针对cd19和cd22的双靶点star

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090791A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
WO2019226998A1 (en) * 2018-05-25 2019-11-28 The Regents Of The University Of California Genetic engineering of endogenous proteins
WO2021173925A1 (en) * 2020-02-28 2021-09-02 Wisconsin Alumni Research Foundation Nonviral generation of genome edited chimeric antigen receptor t cells
CA3190266A1 (en) 2020-07-30 2022-02-03 Institut Curie Immune cells defective for socs1
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US20250041412A1 (en) 2021-03-11 2025-02-06 Institut Curie Transmembrane neoantigenic peptides
EP4304632A2 (en) 2021-03-11 2024-01-17 Mnemo Therapeutics Tumor neoantigenic peptides
WO2022189639A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
WO2022232016A2 (en) 2021-04-26 2022-11-03 Memorial Sloan-Kettering Cancer Center Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
US20250115916A1 (en) 2022-01-21 2025-04-10 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｍｓｌｎ抗体及び使用方法
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023237541A1 (en) * 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2025125363A1 (en) 2023-12-11 2025-06-19 Institut National de la Santé et de la Recherche Médicale Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
WO2026002973A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Host immune cells engineered to overexpress a foxk1 polypeptide
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091034A1 (en) * 2012-12-14 2014-06-19 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Novel mhc-independent tumor-associated antigens
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US5906936A (en) * 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US20020018783A1 (en) 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
JP6346266B2 (ja) * 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
CN117070468A (zh) * 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
IL297018A (en) * 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
CA3036745A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
PT3583129T (pt) * 2017-02-14 2021-12-14 Kite Pharma Inc Moléculas de ligação a cd70 e seus métodos de uso
US11512287B2 (en) * 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CA3090791A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091034A1 (en) * 2012-12-14 2014-06-19 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Novel mhc-independent tumor-associated antigens
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOAN GOVERMAN ET AL: "Chimeric lmmunoglobulin-T Cell Receptor Proteins Form Functional Receptors: Implications for T Cell Receptor Complex Formation and Activatiin", CELL *
JUSTIN EYQUEM ET AL: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection", NATURE *
曹晓运等: "抗人小细胞肺癌T 细胞受体嵌合基因的克隆", 中国癌症杂志 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022179545A1 (zh) * 2021-02-25 2022-09-01 华夏英泰（北京）生物技术有限公司 针对cd19和cd22的双靶点star

Also Published As

Publication number Publication date
IL276554A (en) 2020-09-30
BR112020016138A2 (pt) 2020-12-15
IL276554B1 (en) 2024-09-01
US11229669B2 (en) 2022-01-25
EP3749687A1 (en) 2020-12-16
WO2019157454A1 (en) 2019-08-15
IL314563A (en) 2024-09-01
US12036244B2 (en) 2024-07-16
US20220031754A1 (en) 2022-02-03
RU2020129818A (ru) 2022-03-11
EP3749687A4 (en) 2021-12-29
IL276554B2 (en) 2025-01-01
AU2019216982B2 (en) 2024-07-04
SG11202007622SA (en) 2020-09-29
JP2021513347A (ja) 2021-05-27
MX2020008390A (es) 2020-12-07
KR102828999B1 (ko) 2025-07-04
JP2025172139A (ja) 2025-11-20
JP2023118962A (ja) 2023-08-25
AU2019216982A1 (en) 2020-08-27
US20200368283A1 (en) 2020-11-26
AU2024220100A1 (en) 2024-10-17
CA3090791A1 (en) 2019-08-15
KR20200120673A (ko) 2020-10-21
US20210030804A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
JP2025172139A (ja) 非ｈｌａ制限ｔ細胞受容体およびその使用
JP7676358B2 (ja) 免疫療法のための融合ポリペプチド
US12544440B2 (en) IL-36 secreting immunoresponsive cells and uses thereof
JP2018504094A (ja) Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
US20230242879A1 (en) Il-33 secreting immunoresponsive cells and uses thereof
JP7668261B2 (ja) 改良された免疫療法のための細胞およびその使用
US20230051064A1 (en) Chimeric antigen receptors with cd28 mutations and use thereof
JP2026017553A (ja) ｃ－Ｋｉｔ変異を発現する細胞およびその使用
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination